ZMZamira Magomedovna Merzhoeva

Zamira Magomedovna Merzhoeva

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Zamira Magomedovna Merzhoeva has a total of 280 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Remote monitoring of patients with chronic obstructive pulmonary disease: results of a multicentre pilot study

    by O.V. Nagatkina, L.YU. Nikitina, B.B. Lavginova, Yu.A. Levina, N.M. Makarova, E.S. Ainetdinova, Z.M. Merzhoeva, G.S. Nuralieva, Z.G. Berikkhanov, O.A. Suvorova, et al.

    Objective. To evaluate the results of a multicentre randomized pilot study of remote monitoring (RM) in patients with chronic obstructive pulmonary disease (COPD). Material and methods. A multicentre, randomized, open-label study. Patients with a verified diagnosis of COPD were randomized 1:1 to either the RM group or the standard follow-up care group (control): a total of 67 patients were enrolled (RM — 33, control — 34). The participation duration was 14 weeks. This paper presents the results of the analysis of patients enrolled at the time of publication preparation (Sechenov University centre). The analysis was performed in the mITT population (N=55: RM 29 patients, control 26). The primary endpoint included: relative change in FEV1, absolute change in the frequency of short-acting bronchodilator (SABD) use, and estimated annual exacerbation rate of COPD at week 12. Results. The relative change in FEV1 at week 12 was +2.65% in the RM group and −6.55% in the control group; the absolute FEV1 value was 70.15% vs 59.99% of predicted (p=0.164). The RM group showed a reduction in the estimated annual COPD exacerbation rate (1.38 vs 2.12; p=0.016); however, this result requires cautious interpretation given the correction for multiple comparisons; the categorical distribution of exacerbations differed significantly (p=0.008). The frequency of SABD use at week 12 was 1.19 vs 1.69 doses/day (p=0.098). The CAT score consistently decreased in the RM group: −2.04 (p=0.021), −2.91 (p=0.020), and −3.33 (p=0.012) at weeks 2, 6, and 12, respectively. The proportion of patients with severe dyspnoea on the Borg scale (≥5 points) was significantly lower in the RM group at week 12 (p=0.027). Mean adherence to monitoring exceeded 80% across all parameters. No unplanned healthcare visits were recorded in the RM group vs 3 cases (11.54%) in the control group (p=0.099). Conclusion. The RM group demonstrated a reduction in the estimated annual COPD exacerbation rate, as well as sustained positive trends in functional and symptomatic outcomes. High patient adherence confirms the feasibility of the RM programme in real-world practice. The findings highlight the need to continue the study in order to obtain more robust data.

  • Characteristics of phenotype combinations in late-onset bronchial asthma

    by T.U. Bogatyreva, V.V. Gaynitdinova, Z.M. Merzhoeva, E.S. Ainetdinova, A.S. Zhuravlev, S.N. Avdeev

    Bronchial asthma (BA) is a heterogeneous disease characterized by a diversity of clinical manifestations, pathophysiological mechanisms, inflammatory patterns, and responses to therapy. In recent years, increasing attention has been paid to late-onset asthma — a variant of the disease in which the first symptoms appear after the age of 40 years. Late-onset asthma is characterized by considerable clinical heterogeneity, frequent coexistence with comorbid conditions, and a variety of phenotypic and endotypic features that largely determine the course and prognosis of the disease. Objective. To study the clinical, functional, laboratory, and instrumental characteristics of different phenotypes of late-onset bronchial asthma, in order to clarify the features of the disease course and optimize a personalized approach to therapy. Material and methods. The study included 130 patients with a confirmed diagnosis of late-onset bronchial asthma who were hospitalized in a specialized pulmonology department. The diagnosis of BA was verified according to the Global Initiative for Asthma (GINA) criteria. Late onset was defined as the occurrence of first asthma symptoms after 40 years of age. Results and conclusion. Late-onset asthma is characterized by the coexistence of several phenotypes in a single patient. The accumulation of phenotypic traits (up to four) is associated with the most severe, uncontrolled disease course, marked decline in lung function, and enhanced eosinophilic inflammation, and may serve as a marker of poor prognosis. Identification of specific phenotypic combinations allows prediction of disease course and optimization of personalized therapy.

  • Open Access

    Triple combination ivacaftor + tezacaftor + elexacaftor and ivacaftor for cystic fibrosis: clinical efficacy and safety of the original drug and its generic analogue Trilexa®

    by Z. M. Merzhoeva, I. A. Levina, B. B. Lavginova, O. A. Suvorova, N. Yu. Kashirskaya, S. N. Avdeev, З. М. Мержоева, Ю. А. Левина, Б. Б. Лавгинова, О. А. Суворова, et al.

    Triple CFTR modulator therapy with ivacaftor + tezacaftor + elexacaftor and ivacaftor (ITE) has substantially changed the clinical course and prognosis of cystic fibrosis. The expanding use of the bioequivalent generic Trilexa® highlights the need to summarize evidence on its clinical efficacy and safety, including outcomes after switching from the originator Trikafta®. The aim of this study was to summarize and systematize national and international data on the efficacy and safety of triple CFTR modulator therapy with ITE, including the experience of using the original drug and the generic drug, in children and adults with cystic fibrosis. Results. The triple ITE combination is the most widely studied and the most effective of the available methods of pathogenetic therapy for cystic fibrosis. In randomized clinical trials and observational programs, the originator provides an increase in FEV 1, a marked reduction in sweat chloride concentration, improvement in nutritional status, and a significant decrease in the rate of pulmonary exacerbations. Bioequivalence of the generic drug has been confirmed. Russian multicenter and regional studies convincingly show that switching from the originator to bioequivalent generic is accompanied by maintenance of FEV1, FVC, nutritional status, and surrogate markers of CFTR function, while preserving a favorable safety profile. The accumulated clinical experience includes the first documented case of a successfully completed pregnancy and delivery under treatment with a generic ITE regimen. Data from studies evaluating the efficacy and safety of deutivacaftor + tezacaftor + vanzacaftor as a new option for triple CFTR modulator therapy were additionally reviewed. Conclusion. The body of evidence from international randomized clinical trials, registry studies, and Russian regional experience indicates clinical comparability between the originator and bioequivalent generic when switching from one to another. The use of a bioequivalent generic is a justified strategy to improve the availability of pathogenetic treatment with the goal to expand access to targeted therapy.

  • Open Access

    Predictors of suboptimal peak inspiratory flow in patients with COPD exacerbation

    by N. V. Trushenko, B. B. Lavginova, G. V. Nekludova, A. A. Metalnickov, Z. M. Merzhoeva, S. N. Avdeev, Н. В. Трушенко, Б. Б. Лавгинова, Г В. Неклюдова, А. А. Метальников, et al.

    Incorrect inhalation technique is one of the main causes of ineffective inhaled therapy in patients with chronic obstructive pulmonary disease (COPD), leading to increased frequency of exacerbations and hospitalizations. Measuring peak inspiratory flow (PIF) and determining its optimal values for a specific dry powder inhaler (DPI) can significantly assist in selecting COPD maintenance therapy. The aim of this study was to determine the frequency and predictors of suboptimal PIF among patients hospitalized due to COPD exacerbation. Methods. The study included 100 patients with COPD exacerbation requiring hospitalization. The analysis comprised basic demographic, clinical, and functional patient characteristics at admission and discharge. PIF was assessed using an IngalOk device at resistance levels corresponding to the DPIs used by patients as maintenance therapy. Measurements were taken before and after training on proper inhalation technique upon hospital admission, as well as before discharge. Results. At admission, suboptimal PIF values were initially recorded in 46% of patients. However, this rate decreased to 20% (p < 0.0001) after training in proper inhalation technique. ROC analysis identified independent predictors of suboptimal PIF such as age > 70 years, FVC < 70% pred., FEV 1 < 30%pred., RV/TLC > 70%pred.. The most significant predictors were age (OR – 0.79; 95% CI – 0.68 – 0.91; p = 0.001) and FEV1pred. (OR – 1.15; 95% CI – 1.09 – 1.25; p = 0.002). Conclusion. The likelihood of suboptimal PIF values should be considered when selecting an optimal inhalation device for maintenance therapy in patients with COPD exacerbation, especially in the elderly, among patients with very severe bronchial obstruction and patients with pulmonary hyperinflation.

  • Open Access

    Clinical characteristics and predictive models of severe asthma risk in patients with late-onset asthma

    by Tamara U. Bogatyreva, Богатырева Тамара Умаровна, Viliya V. Gaynitdinova, Гайнитдинова Вилия Вилевна, Elizaveta S. Aynetdinova, Айнетдинова Елизавета Сергеевна, Andrey S. Zhuravlev, Журавлев Андрей Сергеевич, Zamira M. Merzhoeva, Мержоева Замира Магомедовна, et al.

    Background. Late-onset asthma (after 40 years) is characterized by more severe disease, frequent exacerbations, fixed bronchial obstruction, and high comorbidity; prognostic tools for this age group, including risk models for rehospitalization and mucus plugs, remain insufficiently developed. Aim. To develop and validate predictive models for estimating the probability of frequent severe exacerbations and the presence of mucus plugs on chest X-Ray computed tomography (CT) in hospitalized patients with late-onset asthma. Materials and methods. This prospective study included 130 hospitalized patients with late-onset asthma (71.5% female, mean age 63.5 ± 11.3 years). Clinical, laboratory (IgE, eosinophils, FeNO), and instrumental (spirometry, body plethysmography, chest CT) data were assessed. Logistic regression models with stepwise selection were built for two outcomes: ≥ 2 severe exacerbations within 12 months, and mucus plugs on CT. Evaluation included bootstrap validation (5,000 resamples), the Hosmer–Lemeshow test, and ROC analysis. Results. A T2 endotype was identified in 115 patients (88.5%); the rate of frequent severe exacerbations (≥ 2/year) was 25.4%. The most common phenotypes were allergic, eosinophilic, nonallergic, and asthma with obesity and fixed obstruction; all patients had combinations of these. Mucus plugs on CT were significantly more common with asthma-COPD overlap. Patients with four phenotypes had poorer symptom control and lower pulmonary function. Independent predictors of frequent severe exacerbations were eosinophilic phenotype (OR 3.2, 95% CI 1.3–8.1; p = 0.013) and diabetes mellitus (OR 3.3, 95% CI 1.3–8.8; p = 0.015); AUC 0.726 (95% CI 0.631–0.821), sensitivity 70%, specificity 66%. Reduced PEF% was the only independent predictor of mucus plugs (OR 0.97 per 1% increase, 95% CI 0.95–0.99; p 0.001); AUC = 0.735 (95% CI 0.649–0.821), sensitivity 68.9%, specificity 68.1%. Conclusion. In hospitalized late-onset asthma patients, eosinophilic phenotype and diabetes mellitus are independent predictors of frequent severe exacerbations (OR ~ 3.2–3.3). Reduced PEF% predicts mucus plugs on CT. The models (AUC 0.726–0.735) can be used for risk stratification in routine practice.

  • Open Access

    Triple CFTR modulator therapy in severe cystic fibrosis-associated liver disease: a case report of an adverse outcome and the role of adherence to follow-up

    by Z. M. Merzhoeva, O. A. Suvorova, Iu. A. Levina, B. B. Lavginova, V. N. Antonov, S. N. Avdeev, З. М. Мержоева, О. А. Суворова, Ю. А. Левина, Б. Б. Лавгинова, et al.

    Background. Cystic fibrosis (CF) is a multisystem disease in which liver involvement occurs in 20-40% of patients. The introduction of CFTR modulator therapy has substantially improved the prognosis of patients with CF; however, patients with established cirrhosis have typically been excluded from clinical trials, which limits the evidence base and underscores the need to collect and publish data on the use of these agents in this patient group. Materials and methods. We report a case with an unfavorable outcome in a 19-year-old patient with CF-associated Child-Pugh class B cirrhosis complicated by portal hypertension and a previous episode of esophageal variceal bleeding. Triple CFTR modulator therapy with elexacaftor + tezacaftor + ivacaftor/ivacaftor was initiated as a life-saving measure at a reduced dose in order to stabilize the patient until a decision on liver transplantation could be made. However, following subjective improvement in respiratory status, the patient was lost to specialist follow-up for approximately two years, during which liver function was not monitored and the transplant workup was not advanced; this culminated in decompensation of cirrhosis (Child-Pugh class C), multiorgan failure, and death. Conclusion. This case demonstrates that in severe CF-associated liver disease the safety of highly effective targeted therapy depends not only on the choice of drug and the dosing regimen, but also on the continuity of specialist follow-up, regular assessment of liver function, timely adjustment of treatment and transplant strategy, and the patient's adherence to follow-up.

  • Open Access

    Follow-up of patients with interstitial lung diseases by a primary care physician. Guidelines

    by O. M. Drapkina, S. N. Avdeev, I. V. Bukhtiyarov, M. I. Smirnova, M. Yu. Kryakova, R. N. Shepel, V. A. Nevzorova, I. A. Viktorova, L. Yu. Drozdova, P. V. Ipatov, et al.

    Interstitial lung diseases are a heterogeneous group of pathologies, the most common of which is idiopathic pulmonary fibrosis. The causes of interstitial diseases often remain unknown, but their pathogenesis is based on the gradual replacement of normal lung tissue with fibrous tissue. More than half of patients with interstitial lung diseases experience fibrosis progression, worsening symptoms, and the onset of respiratory failure within 2 years of diagnosis. Early diagnosis and timely follow-up are the primary means of disease management, particularly for idiopathic pulmonary fibrosis. This includes slowing disease progression, reducing the frequency and severity of exacerbations, and reducing the risk of developing and progressing different acute and chronic conditions that can affect respiratory symptoms and the prognosis of interstitial lung diseases. These guidelines are intended for primary care physicians, general practitioners, nurses working with these physicians, and paramedics at primary care facilities performing the doctor functions, including conducting outpatient follow-up. These guidelines are also intended for specialists such as pulmonologists, allergists/ immunologists, and other specialists involved in the care of patients with interstitial lung diseases. In addition, these guidelines are intended for heads of healthcare facilities (or its divisions) providing primary care, as well as students, residents, and postgraduate students at medical and pharmaceutical educational institutions.

  • Open Access

    Clinical and functional predictors of pulmonary hypertension in patients with idiopathic pulmonary fibrosis

    by A. A. Proshkina, N. A. Tsareva, G. V. Nekludova, K. S. Ataman, D. O. Zhukova, Z. M. Merzhoeva, V. V. Gaynitdinova, S. N. Avdeev, А. А. Прошкина, Н. А. Царева, et al.

    Introduction . Idiopathic pulmonary fibrosis (IPF) is frequently complicated by pulmonary hypertension (PH), the prevalence of which reaches 50–80% among patients awaiting lung transplantation. At the same time, the accuracy of transthoracic echocardiography as the main screening method for PH in patients with IPF is limited, which determines the need for simple non-invasive functional tests to select patients for further in-depth evaluation. Aim . To determine the clinical and functional predictors of pulmonary hypertension in patients with idiopathic pulmonary fibrosis. Materials and methods. The study included 121 patients with IPF. Based on echocardiography findings, the patients were divided into two groups: without PH (PASP Results . The groups did not differ significantly in age, sex, BMI, or smoking status. In patients with PH, cardiovascular events were significantly more frequent (59 vs. 26%, p < 0.001), as was chronic heart failure (55 vs. 23%, p = 0.001). The Charlson Comorbidity Index (p = 0.027) and dyspnea severity according to the mMRC scale (p = 0.022) were higher in the PH group. Absolute DLCO was lower in the PH group (8.5 vs. 10.1 mL/min/mmHg, p = 0.041). The level of desaturation during the 6MWT was higher, and post-6MWT SpO₂ was lower in the PH group (p = 0.002 and p = 0.001, respectively). ROC analysis identified the following cut-off values: post-6MWT SpO₂ 9%, post-6MWT SpO₂ <84%) may be utilized for screening purposes.

  • Open Access

    Echocardiographic determinants of pulmonary hypertension in patients with idiopathic pulmonary fibrosis: Association with clinical and functional status

    by A. A. Proshkina, N. A. Tsareva, G. V. Nekludova, K. S. Ataman, D. O. Zhukova, Z. M. Merzhoeva, V. V. Gaynitdinova, S. N. Avdeev

    Introduction . Pulmonary hypertension (PH) frequently complicates the course of idiopathic pulmonary fibrosis (IPF) and worsens its prognosis; however, echocardiographic signs of right heart chamber remodeling and clinical and functional factors associated with systolic pulmonary artery pressure (PASP) level in IPF remain insufficiently studied. Aim . To characterize echocardiographic changes in the right heart chambers in patients with idiopathic pulmonary fibrosis depending on the presence of pulmonary hypertension and to identify clinical and functional factors associated with the value of systolic pulmonary artery pressure. Materials and methods. The study included 121 patients with IPF. Based on echocardiography, patients were divided into groups without PH (PASP < 35 mmHg, n = 35) and with PH (PASP ≥ 35 mmHg, n = 86). Right atrial area (RA area), mean right ventricular diameter (RV diameter), TAPSE, TAPSE/PASP ratio, and left ventricular ejection fraction (LVEF) were assessed. Spearman correlation analysis, univariate and multivariate linear regression analysis with PASP as a continuous variable were performed. Results. The PH group showed larger RA area (17.0 vs 13.5 cm², p < 0.001), larger RV diameter (4.00 vs 3.75 cm, p < 0.001), and a lower TAPSE/PASP ratio (0.438 vs 0.697, p < 0.001) with no difference in absolute TAPSE (p = 0.941). LVEF was slightly lower in the PH group (61% vs 62%, p = 0.016) but remained within normal limits. PASP correlated positively with RA area (r = 0.491, p = 0.019) and desaturation level during 6MWT (r = 0.355, p < 0.001), and negatively with post-exercise SpO₂ (r = -0.336, p = 0.001). DLCO correlated positively with post-exercise SpO₂ (r = 0.347, p = 0.001) and negatively with mMRC (r = -0.338, p = 0.001) and desaturation (r = -0.270, p = 0.014). Univariate linear regression showed associations of PASP with cardiovascular events (β = 10.8), CHF (β = 10.9), desaturation (β = 1.02 per 1%), post-exercise SpO₂ (β = -0.603), mMRC (β = 4.52), LTOT duration (β = 3.74 per year), and LVEF (β = -0.562). In multivariate linear regression, independent determinants of PASP were the Charlson comorbidity index (β = 2.205 per 1 point; p = 0.006), desaturation level (β = 1.153 per 1%; p < 0.001), and LTOT duration (β = 4.281 per year; p = 0.020). Conclusion . In patients with IPF, pulmonary hypertension is associated with right heart remodeling (enlarged RA area, RV diameter) and reduced right ventricular-pulmonary arterial coupling (decreased TAPSE/PASP ratio) despite preserved TAPSE. Independent determinants of PASP value are comorbidity burden (Charlson index), desaturation during exercise, and long-term oxygen therapy duration.

  • Open Access

    Clinical and functional characteristics, endotypes, and phenotypes of lateand very late-onset asthma

    by T. U. Bogatyreva, V. V. Gaynitdinova, Z. M. Merzhoeva, E. S. Aynetdinova, A. S. Zhuravlev, H. Wang, A. A. Aktalieva, Т. У. Богатырева, В. В. Гайнитдинова, З. М. Мержоева, et al.

    Introduction . One of the most common phenotypes in Russia is eosinophilic bronchial asthma (BA) with late onset. The term “asthma with late onset” refers to a condition where symptoms similar to BA first appear in a person over 40 years of age. The high prevalence of comorbid conditions significantly complicates the diagnosis and treatment of late-onset asthma. Aim. To study the features of the clinical course and laboratory-functional indicators in patients with bronchial asthma of late and very late onset. Materials and methods . A prospective observational study included 130 hospitalized patients with late-onset bronchial asthma. All patients had a documented diagnosis of “bronchial asthma” based on GINA clinical criteria. The late-onset bronchial asthma phenotype was defined as the onset of BA symptoms at an age older than 40 years. The very late-onset bronchial asthma phenotype was defined as the onset of BA symptoms at an elderly age (older than 60 years, according to WHO). Results. The mean age of the patients was 63.5 ± 11.3 years, and the age of BA onset was 51.5 (42–62) years. Women predominated among the patients (71.5%). The majority (88.5%) had a T2 endotype of BA, which included allergic and/or eosinophilic phenotypes, was characterized by reversible obstruction (53.9% vs. 0% in the non-T2 group, p < 0.001) and higher lung diffusing capacity (p = 0.035). The non-T2 endotype was characterized by a non-allergic phenotype, a higher frequency of combination with COPD (46.7 vs 20.0%, p = 0.044) and bronchiectasis (46.7 vs 19.1%, p = 0.041). The course of asthma was predominantly uncontrolled (86.2%) with frequent exacerbations. Patients with very late onset (≥60 years) had more pronounced impairments in external respiratory function, a decrease in air flow rate in the small airways (decrease in MEF₅₀, MEF₇₅, PEF; p < 0.05), and statistically significantly more often suffered from coronary artery disease (66.7 vs 42.9%, p = 0.013). Conclusion. Late-onset BA is characterized by a predominance of the T2 endotype, a severe uncontrolled course, and high comorbidity. Bronchial asthma with a very late onset (≥60 years) has more pronounced impairments in external respiratory function, signs of systemic inflammation, a lower frequency of exacerbations during the year, and a more frequent combination with cardiovascular diseases.